Elekta AB Class B
EKTAF
Market Cap$2.33B
Close$
$3.37
46.8% downside
Current Fair Value
46.8% downsideOvervalued by 46.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $2.4 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 368,587,640 |
| Avg 30 Day Volume | 533 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Elekta AB
CEO: Gustaf Salford Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...